Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia

Core Viewpoint - Idorsia Ltd announces the appointment of Dr. Srishti Gupta as the new CEO effective July 1, 2025, succeeding André C. Muller, who will transition to an advisory role to ensure a smooth leadership change [1][3][4]. Group 1: Leadership Transition - Dr. Srishti Gupta has been a board member since 2021 and is well-positioned to lead the company due to her deep understanding of Idorsia's operations and product portfolio [1][2]. - André C. Muller, the current CEO, will retire and take on an advisory role, having successfully led the company through financial restructuring and the commercial ramp-up of QUVIVIQ in the EUCAN region [3][4]. - The leadership transition aims to maintain stability and continuity as the company focuses on advancing its product portfolio and achieving profitability by the end of 2027 [4][5]. Group 2: Dr. Srishti Gupta's Background - Dr. Gupta has over 20 years of experience in global health and biopharmaceutical innovation, with a strong background in strategy and healthcare systems [2][8]. - She previously spent 18 years at McKinsey & Company, where she held senior leadership roles in the pharmaceutical and global health practices [2][9]. - Dr. Gupta holds an MD from Harvard Medical School and multiple degrees from Harvard University and the University of Cambridge, showcasing her strong academic credentials [8][9]. Group 3: Company Outlook - The company is optimistic about the commercial success of QUVIVIQ, which is gaining traction in Europe, and is reactivating collaboration discussions for TRYVIO [5][12]. - Dr. Gupta emphasizes the need for balancing ambition with financial discipline, indicating a focus on smart investments in promising assets [5][6]. - Idorsia aims to evolve into a leading biopharmaceutical company, committed to discovering and commercializing transformative medicines [11][12].